“Run a compliance review and tell us whether the AI workflow is HIPAA or GxP ready.” That request, taken literally, produces a findings memo. A memo describes where you stood on the day someone wrote it — and the day an auditor arrives, it is already stale, because nobody captured the evidence that the controls it described actually operated.
A readiness engagement structured as evidence production ends differently. Every step of the clinical workflow is walked with the people who own it, and each step leaves the room with one of two things attached to it: a named evidence item filed into the pack, or a logged gap carrying an owner and a close date. Nothing stays in the ambiguous middle. What ships at handoff is a populated HIPAA / GxP evidence pack plus a countable gap list, not an assessment.
The distinction matters because of what teams actually discover at first audit. In the regulated deployments we have supported, the controls are usually present and correctly configured — access is role-based, data handling is documented, the model was tested. What is missing is producible proof that each control operated on the regulated step in question, on a date, attributable to a person. That is an evidence-capture failure, not a controls failure, and a review-shaped engagement is structurally unable to fix it.
What does a clinical workflow readiness engagement produce?
Two deliverables, and they are the point of the exercise rather than appendices to it.
The first is the populated pack: access trails, data-handling lineage, change-control sign-offs, training records, and per-step validation evidence, filed against the pack’s section structure. The section-by-section anatomy of the pack sets what each slot must hold; the readiness engagement is what fills those slots from artefacts that already exist inside the deployment.
The second is the gap log. Any workflow step where no artefact can be produced becomes a row with a named owner and a close date, tracked to zero before go-live. This is the mechanism that turns readiness from a judgement call into arithmetic: at any moment during the engagement, someone can state how many regulated steps have complete evidence and how many are open.
How the engagement is sequenced
The walkthrough is the load-bearing phase. It is run with the clinical or process owner, the site’s IT function, and quality present at the same time — not sequentially, because the interesting disagreements are about who owns an artefact, and those only surface when all three parties hear the same question.
| Phase | What happens | What leaves the phase |
|---|---|---|
| Workflow decomposition | Enumerate every step that touches regulated data or produces a regulated output, including non-human actors: inference services, retrieval steps, batch re-scoring, model-update pipelines | A numbered step list that becomes the pack’s spine |
| Evidence walkthrough | Step by step, ask who can produce the access trail, lineage record, sign-off, training record and validation result — and ask them to produce it, not describe it | Filed evidence items, or gap rows |
| Ownership assignment | Resolve which function supplies each item; contested items are gaps until an owner accepts them | An owner name against every pack section |
| Gap closure | Owners close rows; each closure is a filed artefact, not a status update | Gap count trending to zero |
| Handoff | Compliance walks the pack as an auditor would, section by section, and raises follow-ups before an external auditor can | Pre-audited pack plus residual gap list with dates |
The handoff phase is where the engagement earns its keep. Compliance running a dry audit against a populated pack is cheap; an external auditor running the same walk against an empty one is not.
Who supplies which evidence
The most common cause of a stalled readiness engagement is not a missing control but an unassigned artefact — three parties each reasonably assuming another owns it.
- The AI vendor or engineering team supplies model provenance, version pinning, the intended-use statement, change-control records for the workflow’s software, and validation evidence for model behaviour against defined acceptance criteria. In practice this is the part that requires the most retrofitting, because pipelines built with MLflow, Docker images, and Kubernetes deployments record plenty of operational history without recording it in an attributable, dated shape.
- Site IT supplies access trails, retention configuration, network and hosting posture, and the export capability that lets an auditor read a log without engineering help.
- Quality and regulatory supply the SOP routing, the change-control approval chain, and the mapping from controls to the regulation clauses they satisfy.
- Clinical operations supply training records, the actual as-run workflow (which routinely diverges from the documented one), and confirmation of who is authorised to act at each step.
Where per-step validation evidence for clinical-imaging steps is concerned, the readiness engagement produces the artefact but does not design the protocol; that boundary is worth holding explicitly, and it belongs to validation work. The structural governance argument behind all of this — why the pack is the unit of compliance rather than the control set — sits in our AI governance and trust practice.
What the second site costs
Because the pack structure is invariant, a second site’s readiness engagement is materially cheaper than the first. The decomposition, the control-to-requirement mapping, the model provenance, and the validation protocol design carry over unchanged. What must be re-produced is per-site: this site’s access grants, this site’s SOP routing for sign-offs, this site’s equipment or scanner fleet in the validation evidence, this site’s training records. The engagement narrows from “build the mapping and fill it” to “fill a known mapping” — which is also why the portability boundary between invariant and per-site layers is worth drawing before the first site finishes rather than after the second one starts.
Where the readiness pass stops
Here the Clinical Workflow Readiness Engagement picture narrows. It does not decide whether the model’s performance is clinically acceptable — that is a defined-intended-use question with its own acceptance criteria and its own owner. It does not write regulatory submission narrative, which answers a different audience’s obligations entirely. And it does not substitute for the validation protocol design that per-step evidence executes against.
Naming those boundaries early is what keeps the engagement finishing on time. Scope creep in readiness work almost always arrives as a validation question or a submission question wearing readiness clothes, and accepting it converts a bounded evidence-production pass back into the open-ended project the engagement structure exists to avoid.
Frequently Asked Questions
What does a clinical workflow readiness engagement that produces the evidence pack mean in practice? Clinical Workflow Readiness Engagement demands rigorous evidence generation before any system goes live. It means the engagement’s output is the artefact itself rather than an opinion about it. Every regulated workflow step is walked with its owners and either yields a filed evidence item or a logged gap. At the end you hold a populated pack and a countable gap list, not a findings memo.
How is the engagement sequenced — what happens in the workflow walkthrough, and what is produced at each phase? Five phases: workflow decomposition (a numbered step list including non-human actors), the evidence walkthrough (produce, don’t describe), ownership assignment, gap closure, and handoff. Each phase has a defined output, and the walkthrough is run with clinical, IT and quality in the room simultaneously so ownership disputes surface immediately.
Who supplies which evidence: which items come from the AI vendor, which from the site’s IT and quality functions, and which from clinical operations? Engineering supplies model provenance, version pinning, intended-use statement and software change control. Site IT supplies access trails, retention settings and log export. Quality supplies SOP routing and the control-to-requirement mapping. Clinical operations supply training records and the as-run workflow.
What does the gap log look like when a workflow step has no producible evidence, and how is closure tracked to go-live? Each gap is a row naming the step, the missing artefact, an accepting owner and a close date. Closure requires a filed artefact, not a status update, so the count is unambiguous. The target is zero open rows before go-live rather than discovery during audit.
What ships at handoff, and how does compliance use the pack to pre-audit before an external auditor arrives? Handoff delivers the populated pack, the section-to-owner map, and any residual gaps with dates. Compliance then walks the pack section by section exactly as an auditor would, raising follow-ups internally while there is still time to close them.
How much of the engagement repeats at a second site, and what carries over because the pack structure is invariant? The structure, control-to-requirement mapping, model provenance, intended-use statement and validation protocol design carry over. What repeats is per-site: local access grants, local SOP routing for sign-offs, local equipment in the validation evidence, and local training records.
Where does this readiness engagement stop — what questions belong to validation work or regulatory submission rather than to the readiness pass? Readiness answers producibility only. Whether model performance meets acceptance criteria against a defined intended use is validation work; what a regulator needs in a dossier is submission work. Both have different owners and lifecycles, and folding them in is the most reliable way to make a bounded engagement unbounded.
The honest read on Clinical Workflow Readiness Engagement
Clinical Workflow Readiness Engagement is rarely the hard part — knowing which of its failure modes you can live with is. That answer is workload-specific, and it is worth writing down before you build.
